Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Marina PulidoGuilhem RoubaudAnne-Laure CazeauHakim MahammediLionel VedrineFlorence JolyLoic MoureyChristian PfisterAlejandro GobernaBarbara LortalCarine BelleraPhilippe PourquierNadine Houédé

Published in: BMC cancer (2018)

ClinicalTrials.gov Identifier: NCT01827943 (trial registration date: October 29, 2012); Retrospectively registered.

Keyphrases

study protocol
clinical trial
phase iii
randomized controlled trial
combination therapy